AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19170462
Drug: Integrative behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrative behavioral couple therapy
Trial: 19170462
Drug: Traditional behavioral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional behavioral couple therapy
Trial: 6515368
Drug: salbutamol 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salbutamol 0.2 mg
Trial: 8584530
Drug: fenoterol 0.2
RxNorm normalized name: fenoterol 0.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenoterol 0.2 mg
Trial: 8584530
Drug: salmeterol 0.05
RxNorm normalized name: salmeterol 0.05 MG/ACTUAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmeterol 0.05 mg
Trial: 2245947
Drug: Lactate gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate gel (5 ml, pH 3.8) inserted into the vagina daily for 7 consecutive days, followed by prophylactic treatment 3 days monthly for 6 months
Trial: 2245947
Drug: Lactate gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate gel
Trial: 17531279
Drug: Ivermectin low
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin low dose (25 microg/kg)
Trial: 17531279
Drug: Ivermectin standard
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin standard dose (150 microg/kg)
Trial: 17531279
Drug: Ivermectin low
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin low dose (25 microg/kg) with second dose after 15 days
Trial: 9643622
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution containing 80 mg sotalol and 20 mg cisapride
Trial: 9643622
Drug: Sublingual tablet
RxNorm normalized name: Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablet of 80 mg sotalol
Trial: 7895388
Drug: Budesonide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (200 micrograms twice a day)
Trial: 7895388
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) (200 micrograms twice a day)
Trial: 23905373
Drug: Buyang Huanwu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buyang Huanwu Decoction (BHD) combined with Aspirin (ASP)
Trial: 23905373
Drug: Clopidogrel and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel and Aspirin (ASP)
Trial: 9360513
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose step-up regimen
Trial: 2981292
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with co-trimoxazole prophylaxis
Trial: 2981292
Drug: Standard-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose chemotherapy without co-trimoxazole prophylaxis
Trial: 26166531
Drug: General knowledge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General knowledge of routine treatment and care (Control)
Trial: 8922243
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy and RT
Trial: 3215626
Drug: 2.5 MU
RxNorm normalized name: benzocaine/cetylpyridinium chl 10-2.5 MUCOUS MEM TROCHE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 MU rIFN-alpha/m2 body surface 3 times weekly i.m. during 6 months
Trial: 3215626
Drug: 5 MU
RxNorm normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 MU rIFN-alpha/m2 body surface 3 times weekly i.m. during 6 months
Trial: 3215626
Drug: 10 MU
RxNorm normalized name: saliva substitute comb no.10 MUCOUS MEM POWDER IN PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 MU rIFN-alpha/m2 body surface 3 times weekly i.m. during 6 months
Trial: 29661382
Drug: Manual Infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual Infusion
Trial: 28895933
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein intake (HP) group (n = 11) received a dietary plan with 1.2 g·kg‐1·day‐1 of protein
Trial: 28895933
Drug: Normal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal protein (NP) group (n = 12) ingested 0.8 g·kg‐1·day‐1 of protein (RDA recommendation)
Trial: 23234880
Drug: EHT 0202
RxNorm normalized name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl Injection [Altuviiio]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHT 0202 (40 and 80 mg bid)
Trial: 22059476
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid (LdAA) preoperatively (≤320 mg daily)
Trial: 22059476
Drug: No low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: No low-dose acetylsalicylic acid (LdAA) preoperatively
Trial: 22059476
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid (LdAA) preoperatively
Trial: 14721997
Drug: Biventricular pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biventricular pacing (resynchronization therapy)
Trial: 9765759
Drug: Postoperative cisplatin-based
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative cisplatin-based chemotherapy alone
Trial: 9765759
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy with radiotherapy
Trial: 9765759
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy with alkylating agents
Trial: 9765759
Drug: Prolonged adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged adjuvant chemotherapy (busulfan or cytoxan daily for 2 years)
Trial: 9765759
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with cyclophosphamide doxorubicin-cisplatin (CAP)
Trial: 9765759
Drug: Current chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current chemotherapy regimens
Trial: 3320136
Drug: Family-patient teaching
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-patient teaching programme (twice a week)
Trial: 27493100
Drug: Probucol 250
RxNorm normalized name: probucol 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 250 mg/d
Trial: 27493100
Drug: Probucol 500
RxNorm normalized name: probucol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 500 mg/d
Trial: 25795699
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF; lenograstim) 15 µg/kg body weight daily on days 1-5
Trial: 25795699
Drug: G-CSF 15
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF 15 µg/kg body weight daily on days 1-5 followed by leukapheresis, isolation and aliquoting of CD133+ cells, infusion of freshly isolated CD133+ cells immediately and frozen doses at days 30 and 60 (0.2×10(6) cells/kg for each of the three doses)
Trial: 23912172
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prophylactic antibodies)
Trial: 11064850
Drug: Exercise alone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise alone, details on dosage and duration not specified
Trial: 8630721
Drug: Extended-release albuterol
RxNorm normalized name: albuterol Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release albuterol tablets (4 mg twice daily, increasing up to 12 mg q 12h)
Trial: 8161670
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg q.d.s.)
Trial: 3948141
Drug: Interferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2a (Roferon‐A), 36 X 10(6)U intramuscularly 3 times weekly
Trial: 3948141
Drug: Interferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2a (Roferon‐A) in combination with vinblastine, 0.10‐0.15 mg/kg intravenously every 2 to 3 weeks
Trial: 26275686
Drug: Cyclosporine-A 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine-A 0.05% ophthalmic emulsion
Trial: 22488662
Drug: Cohorts 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts 1 + 2 (n = 68) with standard induction therapy
Trial: 22488662
Drug: Cohort 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 3 (n = 141) with modified induction therapy (prednisone 40 mg/m(2)/day, short infusion daunorubicin 30 minutes)
Trial: 20007756
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium (CS) 135 mg three times daily for 8 weeks
Trial: 12605350
Drug: Agnus castus
RxNorm normalized name: Vitex agnus-castus whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agnus castus (AC: 120 ‐ 480 mg/die) for 14 days
Trial: 6151504
Drug: Propranolol (1-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (1-8 mg)
Trial: 6151504
Drug: Pindolol (0.1-0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (0.1-0.8 mg)
Trial: 6151504
Drug: Single i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single i.v. Propranolol (8 mg)
Trial: 6151504
Drug: Single i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single i.v. Pindolol (0.8 mg)
Trial: 20190601
Drug: Landiolol (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol (treatment L)
Trial: 20190601
Drug: Control (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (treatment C)
Trial: 11827919
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (warfarin plus aspirin)
Trial: 10406248
Drug: Flumazenil (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.01 mg/kg, maximum 1.0 mg)
Trial: 12118494
Drug: Placebo (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous normal saline)
Trial: 7555258
Drug: oral low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral low-dose acyclovir (600-800 mg per day)
Trial: 1701507
Drug: topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical corticosteroids in combination with antibiotics
Trial: 31631361
Drug: Three fractional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three fractional ablative CO2 laser treatments at 8‐week intervals
Trial: 25009161
Drug: Olanzapine (OLZ)
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine (OLZ) 2.5‐20 mg/d
Trial: 25009161
Drug: Conventional antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antipsychotic (CNV)
Trial: 23720078
Drug: Tramadol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (2 mg.kg-1)
Trial: 23720078
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg.kg-1)
Trial: 21630032
Drug: omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 fatty acids (1 g twice daily)
Trial: 15153205
Drug: Remifentanil 2
RxNorm normalized name: remifentanil 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 2 microg.kg(‐1) before propofol 3 mg.kg(‐1)
Trial: 15153205
Drug: Remifentanil 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 3 microg.kg(‐1) before propofol 3 mg.kg(‐1)
Trial: 9572229
Drug: Misoprostol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (50 microg every 4 hours for three doses with or without oxytocin)
Trial: 9572229
Drug: Extra-amniotic saline
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-amniotic saline infusion and oxytocin
Trial: 2568016
Drug: Omeprazole (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (specific dosage and duration not available)
Trial: 2568016
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (specific details not available)
Trial: 2568016
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy (specific details not available)
Trial: 2568016
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of drugs (specific details not available)
Trial: 31101700
Drug: Dextromethorphan 30
RxNorm normalized name: DEXTROMETHORPHAN 30MG/5ML LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 30 mg three times a day
Trial: 31101700
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide inhaler 20 μg two puffs three times a day
Trial: 31101700
Drug: Honey 30
RxNorm normalized name: SIMPLYTHICK ORAL GEL HONEY 30GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey 30 mg (a spoonful) three times a day
Trial: 28605109
Drug: Valnoctamide 1500
RxNorm normalized name: valnoctamide
DrugBank: Valnoctamide (DB13099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valnoctamide 1500 mg/d (n=71)
Trial: 28605109
Drug: Risperidone 6
RxNorm normalized name: risperidone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 6 mg/d (n=32)
Trial: 25470423
Drug: Low-intensity extracorporeal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity extracorporeal shockwave therapy (LI-ESWT)
Trial: 21136213
Drug: Navcap (V
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navcap (V 25 mg/m2 on d1 and d8 and C 825 mg/m2 bid D1‐14 q3w) for 4 cycles followed by Navcap (A)
Trial: 21136213
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel (25 mg/m²/week) for 12 cycles (B)
Trial: 17519305
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/d for 3 months
Trial: 15122531
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all three specimens (first-void urine, urethral swabs, semen)
Trial: 9566830
Drug: Silymarin (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (450 mg, 150 mg three times per day)
Trial: 8169656
Drug: Sustained‐release ferrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained‐release ferrous sulfate (150 mg) daily for 14 weeks
Trial: 8169656
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets daily for 14 weeks
Trial: 3414573
Drug: Balloon filled
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon filled with 400 mL water
Trial: 3414573
Drug: Balloon filled
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon filled with 600 mL water
Trial: 3414573
Drug: Balloon filled
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon filled with 800 mL water
Trial: 3414573
Drug: Balloon filled
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon filled with 0 mL water
Trial: 3414573
Drug: Balloon filled
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon filled with 200 mL water
Trial: 27029284
Drug: One-pill DAPT
RxNorm normalized name: Vitafol-One Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-pill DAPT
Trial: 27029284
Drug: Two-pill DAPT
RxNorm normalized name: Two-Dyne Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-pill DAPT
Trial: 24967362
Drug: Patients positive
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients positive to antinuclear antibodies
Trial: 24967362
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drug users
Trial: 24967362
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration route
Trial: 22643944
Drug: Antibiotics (cefazolin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (cefazolin at 1.0 g i.v.) only at anesthetic induction
Trial: 22643944
Drug: Antibiotics (cefazolin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (cefazolin at 1.0 g i.v. at anesthetic induction and oral amoxicillin at 1 g every 12 hours for 7 days)
Trial: 18482233
Drug: Intravenous propacetamol
RxNorm normalized name: 1,2,3-propanetriol, 2-(4-aminobenzoate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propacetamol (40 mg.kg(‐1) via 15 min infusion)
Trial: 18482233
Drug: Rectal paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal paracetamol (20 mg.kg(‐1) every 6 h)
Trial: 11996473
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF regimen (cyclophosphamide 100 mg/m2 p.o. on days 1 to 14, methotrexate 40 mg/m2 i.v. on days 1 and 8, 5‐fluorouracil 600 mg/ml i.v. on days 1 and 8; cycles q. 28 days)
Trial: 10862204
Drug: Carotid endarterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotid endarterectomy with patch closure (CEAP)
Trial: 28686776
Drug: A/BPO gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/BPO gel 0.3%/2.5%
Trial: 26000685
Drug: Subfascial ultrasound-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subfascial ultrasound-guided stellate ganglion block with 4 mL of 0.375% levobupivacaine (group S)
Trial: 23597267
Drug: Strawberry-flavoured placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strawberry-flavoured placebo preparations
Trial: 21266447
Drug: Dietary plant-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary plant-derived polysaccharide supplement (AC)
Trial: 17174508
Drug: Clarithromycin tablet
RxNorm normalized name: Clarithromycin Tablets
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin tablet formulation 1
Trial: 17174508
Drug: Clarithromycin tablet
RxNorm normalized name: Clarithromycin Tablets
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin tablet formulation 2
Trial: 15098801
Drug: Ondansetron solution
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron solution (4 mg)
Trial: 15098801
Drug: Extemporaneous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extemporaneous ondansetron capsule formulation (4 mg)
Trial: 11408420
Drug: Carbohydrate beverage
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate beverage (1 l/h of a 6% carbohydrate beverage)
Trial: 2493523
Drug: Topical nitroglycerin
RxNorm normalized name: nitroglycerin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitroglycerin ointment (NTG)
Trial: 28455182
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (2 doses of 20 mg/kg)
Trial: 28455182
Drug: Topical TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TXA (3.0 g)
Trial: 28455182
Drug: Oral TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TXA (2 doses of 20 mg/kg)
Trial: 27208386
Drug: DIMS0150 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIMS0150 (30 mg)
Trial: 17532963
Drug: MC-1 250
RxNorm normalized name: MC-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MC-1 250 mg
Trial: 15478487
Drug: Self-etching agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etching agents (Prompt‐L Pop, Adper Prompt, Clearfil SE, Prime& Bond NT with NRC, Xeno111, One‐Up Bond, AdheSe)
Trial: 9627258
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine (4 mg/kg of 2% lidocaine applied to subglottic, glottic, and supraglottic areas before intubation)